Clinical Trial Update: A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042 [Phase 1]

View source ↗

Summary

Phase 1 cross-over trial evaluating whether NPT 2042 suppresses the photoparoxysmal EEG response in photosensitive epilepsy has completed, with results not deta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Photosensitive Epilepsy

Drugs mentioned

• NPT 2042

Snippet

Sponsor: NeuroPro Therapeutics, Inc. | Conditions: Photosensitive Epilepsy, Epilepsy | Phase 1 | Status: COMPLETED